此細胞來源于71歲白種女性，這些細胞大多是超二倍體，有51條染色體的尖銳模式數(shù)；偶爾也可以看到超四倍體范圍內(nèi)的細胞。在A、B、C和F組中，始終觀察到一條微小的標記染色體，染色體數(shù)目增加。此細胞非特異性酯酶和酸性磷酸酶陽性。這些細胞對EB病毒核抗原（EBNA-）呈陰性。細胞表面Ig陰性（sIG-）。據(jù)報道，這些細胞呈E-玫瑰花結陰性。曾在ATCC通過PCR證實該細胞系存在EB病毒DNA序列。

組織來源：B淋巴細胞

形態(tài)：淋巴母細胞樣 ，懸浮 多細胞聚集體 生長

培養(yǎng)基配方：

90%1640(MD0200)+10%胎牛血清(SD0200)+G/A (SD0038)

完全培養(yǎng)基：1640完全培養(yǎng)基（MD0201）

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

凍存條件：基礎培養(yǎng)基+5%DMSO+20%FBS(SD0200)

完全凍存液：免程序降溫細胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=4140017; DOI=10.1002/1097-0142(197412)34:6
Epstein A.L., Kaplan H.S.
Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas.
Cancer 34:1851-1872(1974)

PubMed=214220; DOI=10.1002/1097-0142(197811)42:5
Epstein A.L., Levy R., Kim H., Henle W., Henle G., Kaplan H.S.
Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines.
Cancer 42:2379-2391(1978)

PubMed=83902; DOI=10.1002/1097-0142(197901)43:1
Kaplan H.S., Goodenow R.S., Gartner S., Bieber M.M.
Biology and virology of the human malignant lymphomas: 1st Milford D Schulz Lecture.
Cancer 43:1-24(1979)

PubMed=371794
Epstein A.L., Kaplan H.S.
Feeder layer and nutritional requirements for the establishment and cloning of human malignant lymphoma cell lines.
Cancer Res. 39:1748-1759(1979)

PubMed=3881165; DOI=10.1016/0165-4608(85)90186-4
Hecht B.K., Epstein A.L., Berger C.S., Kaplan H.S., Hecht F.
Histiocytic lymphoma cell lines: immunologic and cytogenetic studies.
Cancer Genet. Cytogenet. 14:205-218(1985)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

PubMed=15356658; DOI=10.1038/sj.leu.2403465
Drexler H.G., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma.
Leukemia 18:1569-1571(2004)

PubMed=21179087; DOI=10.1038/nature09671
Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H., Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L., Romesser P., Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M.
Oncogenically active MYD88 mutations in human lymphoma.
Nature 470:115-119(2011)